 PDS Biotechnology Corporation NASDAQ: PDSB has announced interim data from the Phase 2 trial led by the National Cancer Institute NCI evaluating PDS0101 Versamune-HPV16 in combination with two investigational immune-modulating agents - bintrafusp alfa and NHS-IL12 for HPV16 positive cancers. Data were presented at the American Society of Clinical Oncology 2021 Annual Meeting. 